Why New Neurogenic Orthostatic Hypotension Treatments Are Needed!
More than 100,000 patients in the U.S. currently suffer from the disabling symptoms of neurogenic orthostatic hypotension (neurogenic OH or nOH), yet treatment options are extremely limited. The only U.S. Food and Drug Administration (FDA) approved treatment for neurogenic OH:
- Is not yet proven to affect symptoms associated with the disorder
- Causes a range of undesired side effects
- Faces FDA withdrawal from the U.S. market in 2014 if it does not demonstrate symptomatic benefit with its two ongoing studies
In addition, there are several non-pharmacological treatment methods and a handful of off-label medications currently being used with limited results. That’s why new treatment options need to be made available now.
At this time, there is a promising new investigational product for neurogenic OH being reviewed by the FDA for U.S. marketing approval. Because neurogenic OH is a rare disease, it is very important for the FDA and Congress to hear directly from patients, caregivers, advocacy organizations and healthcare providers who understand the disabling symptoms of neurogenic orthostatic hypotension and the negative impact on quality of life.